Scaling safety expertise in life sciences

A turning point in pharmacovigilance

Download PDF Report



Executive overview

Authors: Elenee Argentinis

Connect with author:


, Offering Leader, Watson for Patient Safety,
Louisa Roberts

Connect with author:


, IBM Watson Health Life Sciences,
Heather Fraser

Connect with author:


, Global Lead for Healthcare and Life Sciences

A holistic approach to improving drug and device safety The mission of pharmacovigilance (PV) is to “detect, assess, understand and prevent adverse events (AEs).”1 PV continues to grow more complex, partly due to a continuing rise in AEs, additional channels to monitor and increasingly stringent regulatory requirements. With timeliness and quality of safety operations as critical as ever, cognitive computing offers new capabilities to add speed, scale and consistency to the entire pharmacovigilance process from AE detection, evaluation and reporting, to signal detection and assessment.